April 16 (Reuters) – An experimental once-daily combination
hepatitis C treatment being developed by AbbVie Inc
demonstrated very high cure rates across a wide range of disease
genotypes, according…
The post New AbbVie hepatitis C regimen shows high cure rates -studies appeared first on NASDAQ.